open access

Vol 92, No 8 (2021)
Review paper
Published online: 2021-05-20
Get Citation

Influence of MiRNAs in gestational diabetes mellitus development

Ilona Juchnicka1, Mariusz Kuzmicki1
DOI: 10.5603/GP.a2021.0121
·
Pubmed: 34105757
·
Ginekol Pol 2021;92(8):579-582.
Affiliations
  1. Department of Gynecology and Gynecological Oncology, Medical University of Bialystok, Poland

open access

Vol 92, No 8 (2021)
REVIEW PAPERS Gynecology
Published online: 2021-05-20

Abstract

Gestational Diabetes Mellitus (GDM) is a metabolic disorder that is considered a prediabetes state. According to the International Diabetes Federation every year an increase in the number of women diagnosed with gestational diabetes is being noticed. It is known that GDM can cause many complications during pregnancy and labor. What is more, women with GDM history and their offspring are at risk of developing diabetes in the future. A new factor in the pathogenesis of GDM is epigenetics, which is described as changes in gene expression without directly modifying the DNA sequence. One of its regulating mechanisms is based on microRNA (miRNA). A small non-coding RNA sequence that has an influence on protein formation by suppressing gene expression. A better understanding of the miRNA’s function could potentially lead to their usage as potential new biomarkers or treatment targets. In this article we review the most significant miRNA molecules in gestational diabetes.

Abstract

Gestational Diabetes Mellitus (GDM) is a metabolic disorder that is considered a prediabetes state. According to the International Diabetes Federation every year an increase in the number of women diagnosed with gestational diabetes is being noticed. It is known that GDM can cause many complications during pregnancy and labor. What is more, women with GDM history and their offspring are at risk of developing diabetes in the future. A new factor in the pathogenesis of GDM is epigenetics, which is described as changes in gene expression without directly modifying the DNA sequence. One of its regulating mechanisms is based on microRNA (miRNA). A small non-coding RNA sequence that has an influence on protein formation by suppressing gene expression. A better understanding of the miRNA’s function could potentially lead to their usage as potential new biomarkers or treatment targets. In this article we review the most significant miRNA molecules in gestational diabetes.

Get Citation

Keywords

gestational diabetes mellitus; GDM; miRNA; epigenetics

About this article
Title

Influence of MiRNAs in gestational diabetes mellitus development

Journal

Ginekologia Polska

Issue

Vol 92, No 8 (2021)

Article type

Review paper

Pages

579-582

Published online

2021-05-20

DOI

10.5603/GP.a2021.0121

Pubmed

34105757

Bibliographic record

Ginekol Pol 2021;92(8):579-582.

Keywords

gestational diabetes mellitus
GDM
miRNA
epigenetics

Authors

Ilona Juchnicka
Mariusz Kuzmicki

References (28)
  1. Pridjian G, Benjamin TD. Update on gestational diabetes. Obstet Gynecol Clin North Am. 2010; 37(2): 255–267.
  2. Barbour LA, McCurdy CE, Hernandez TL, et al. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care. 2007; 30 Suppl 2: S112–S119.
  3. Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018; 138: 271–281.
  4. Bortolon L, Triz Ld, Faustino Bd, et al. Gestational Diabetes Mellitus: New Diagnostic Criteria. Open Journal of Endocrine and Metabolic Diseases. 2016; 06(01): 13–19.
  5. O'Sullivan JB, Mahan CM, Charles D, et al. Screening criteria for high-risk gestational diabetic patients. Am J Obstet Gynecol. 1973; 116(7): 895–900.
  6. Sacks DA, Hadden DR, Maresh M, et al. HAPO Study Cooperative Research Group. Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria: the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Diabetes Care. 2012; 35(3): 526–528.
  7. Waddington CH. The epigenotype. 1942. Int J Epidemiol. 2012; 41(1): 10–13.
  8. Wang K, Chang H. Epigenomics. Circulation Research. 2018; 122(9): 1191–1199.
  9. Lee R, Feinbaum R, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5): 843–854.
  10. Grosswendt S, Rajewsky N. Essentials of miRNA-dependent Control of mRNA Translation and decay, miRNA Targeting Principles, and Methods for Target Identification. Essentials of Noncoding RNA in Neuroscience. 2017: 19–38.
  11. Roberts TC. The MicroRNA Biology of the Mammalian Nucleus. Mol Ther Nucleic Acids. 2014; 3: e188.
  12. Vidigal JA, Ventura A. The biological functions of miRNAs: lessons from in vivo studies. Trends Cell Biol. 2015; 25(3): 137–147.
  13. Vishnoi A, Rani S. MiRNA Biogenesis and Regulation of Diseases: An Overview. Methods Mol Biol. 2017; 1509: 1–10.
  14. Dirven BCJ, Homberg JR, Kozicz T, et al. Epigenetic programming of the neuroendocrine stress response by adult life stress. J Mol Endocrinol. 2017; 59(1): R11–R31.
  15. Zhao C, Dong J, Jiang T, et al. Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus. PLoS One. 2011; 6(8): e23925.
  16. Dooley J, Garcia-Perez JE, Sreenivasan J, et al. The microRNA-29 Family Dictates the Balance Between Homeostatic and Pathological Glucose Handling in Diabetes and Obesity. Diabetes. 2016; 65(1): 53–61.
  17. Zhu H, Leung SW. Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies. Diabetologia. 2015; 58(5): 900–911.
  18. Shi Z, Zhao C, Guo X, et al. Differential expression of microRNAs in omental adipose tissue from gestational diabetes mellitus subjects reveals miR-222 as a regulator of ERα expression in estrogen-induced insulin resistance. Endocrinology. 2014; 155(5): 1982–1990.
  19. Zhu Y, Tian F, Li H, et al. Profiling maternal plasma microRNA expression in early pregnancy to predict gestational diabetes mellitus. Int J Gynaecol Obstet. 2015; 130(1): 49–53.
  20. Cao YL, Jia YJ, Xing BH, et al. Plasma microRNA-16-5p, -17-5p and -20a-5p: Novel diagnostic biomarkers for gestational diabetes mellitus. J Obstet Gynaecol Res. 2017; 43(6): 974–981.
  21. Pheiffer C, Dias S, Rheeder P, et al. Decreased Expression of Circulating miR-20a-5p in South African Women with Gestational Diabetes Mellitus. Mol Diagn Ther. 2018; 22(3): 345–352.
  22. Sebastiani G, Guarino E, Grieco GE, et al. Circulating microRNA (miRNA) Expression Profiling in Plasma of Patients with Gestational Diabetes Mellitus Reveals Upregulation of miRNA miR-330-3p. Front Endocrinol (Lausanne). 2017; 8: 345.
  23. Wang Z, Oh E, Thurmond DC. Glucose-stimulated Cdc42 signaling is essential for the second phase of insulin secretion. J Biol Chem. 2007; 282(13): 9536–9546.
  24. Annicotte JS, Blanchet E, Chavey C, et al. The CDK4-pRB-E2F1 pathway controls insulin secretion. Nat Cell Biol. 2009; 11(8): 1017–1023.
  25. Nair S, Jayabalan N, Guanzon D, et al. Human placental exosomes in gestational diabetes mellitus carry a specific set of miRNAs associated with skeletal muscle insulin sensitivity. Clin Sci (Lond). 2018; 132(22): 2451–2467.
  26. Zhu HJ, Pan H, Cui Y, et al. The changes of serum glypican4 in obese patients with different glucose metabolism status. J Clin Endocrinol Metab. 2014; 99(12): E2697–E2701.
  27. Herrera BM, Lockstone HE, Taylor JM, et al. MicroRNA-125a is over-expressed in insulin target tissues in a spontaneous rat model of Type 2 Diabetes. BMC Med Genomics. 2009; 2: 54.
  28. Houshmand-Oeregaard A, Schrölkamp M, Kelstrup L, et al. Increased expression of microRNA-15a and microRNA-15b in skeletal muscle from adult offspring of women with diabetes in pregnancy. Hum Mol Genet. 2018; 27(10): 1763–1771.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl